know about treatment of metastatic breast cancer and hormone
For information about the Treatment of Metastatic Breast Cancer listed below, see the Treatment Option Overview section.
In postmenopausal women who have just been diagnosed with metastatic breast cancer that is hormone receptor-positive or if the hormone receptor status is not known, may include:
- Tamoxifen therapy.
- Aromatase inhibitor therapy (anastrozole, letrozole, or exemestane). Sometimes cyclin-dependent kinase inhibitor therapy (palbociclib, ribociclib, abemaciclib, or alpelisib) is also given.
- An LHRH agonist
- Cyclin-dependent kinase inhibitor therapy (ribociclib)
In women whose tumors are hormone receptor-positive or hormone receptor unknown, with spread to the bone or soft tissue only, and who have been treated with tamoxifen, treatment may include:
- Aromatase inhibitor therapy.
- Other hormone therapy such as megestrol acetate, estrogen or androgen therapy, or anti-estrogen therapy such as fulvestrant.
Targeted therapy for Treatment of Metastatic Breast Cancer
In women with metastatic breast cancer that is hormone receptor positive and has not responded to other treatments, options may include targeted therapy such as:
- Trastuzumab, lapatinib, pertuzumab, or mTOR inhibitors.
- Antibody-drug conjugate therapy with ado-trastuzumab emtansine.
- Cyclin-dependent kinase inhibitor therapy (palbociclib, ribociclib, or abemaciclib) which may be combined with hormone therapy.
In women with mbc that is HER2/neu positive, treatment may include:
- Targeted therapy such as trastuzumab, trastuzumab deruxtecan, pertuzumab, ado-trastuzumab emtansine, or lapatinib.
- Targeted therapy with tucatinib, a tyrosine kinase inhibitor used with trastuzumab and capecitabine
In women with metastatic breast cancer that is HER2 negative, with mutations in the BRCA1 or BRCA2 genes, and who have been treated with chemotherapy, include:
- Chemotherapy for Treatment of Metastatic Breast Cancer
- Targeted therapy with a PARP inhibitor (olaparib or talazoparib)
In women with metastatic breast cancer that is hormone receptor-negative, has not responded to hormone therapy, has spread to other organs or has caused symptoms, treatment may include:
- Chemotherapy with one or more drugs
Chemotherapy and immunotherapy for Treatment of Metastatic Breast Cancer
In women with mbc that is hormone receptor negative and HER2 negative, treatment may include:
- Chemotherapy and immunotherapy (atezolizumab)
- Total mastectomy for women with open or painful breast lesions.
- The Surgery to remove cancer that has spread to the brain or spine.
- To Surgery to remove cancer that has spread to the lung.
- Surgery to repair or help support weak or broken bones.
- Surgery to remove fluid that has collected around the lungs or heart.
- Radiation therapy to the bones, brain, spinal cord, breast, or chest wall to relieve symptoms and improve quality of life.
- Strontium-89 (a radionuclide) to relieve pain from cancer that has spread to bones throughout the body.
Other treatment options
Other treatment options for metastatic breast cancer include:
- Drug therapy with bisphosphonates or denosumab to reduce bone disease and pain when cancer has spread to the bone. (See the PDQ summary on Cancer Pain for more information about bisphosphonates.)
- Antibody-drug conjugate therapy with sacituzumab govitecan for certain patients with metastatic triple-negative breast cancer.
- A clinical trial of high-dose chemotherapy with stem cell transplant.
- Clinical trials testing new anticancer drugs, new drug combinations, and new ways of giving treatment.